SANOFI-ADR (SNY) Stock Fundamental Analysis
NASDAQ:SNY - Nasdaq - US80105N1054 - ADR - Currency: USD
Taking everything into account, SNY scores 5 out of 10 in our fundamental rating. SNY was compared to 194 industry peers in the Pharmaceuticals industry. SNY scores excellent on profitability, but there are concerns on its financial health. SNY has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year SNY was profitable.
SNY had positive earnings in each of the past 5 years.
Of the past 5 years SNY 4 years had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 9.00%, SNY belongs to the top of the industry, outperforming 92.43% of the companies in the same industry.
With an excellent Return On Equity value of 15.37%, SNY belongs to the best of the industry, outperforming 90.81% of the companies in the same industry.
SNY's Return On Invested Capital of 15.58% is amongst the best of the industry. SNY outperforms 92.43% of its industry peers.
SNY had an Average Return On Invested Capital over the past 3 years of 7.46%. This is significantly below the industry average of 44.04%.
The last Return On Invested Capital (15.58%) for SNY is above the 3 year average (7.46%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9% | ||
| ROE | 15.37% | ||
| ROIC | 15.58% |
ROA(3y)5.07%
ROA(5y)6.23%
ROE(3y)8.63%
ROE(5y)10.88%
ROIC(3y)7.46%
ROIC(5y)7.05%
1.3 Margins
With an excellent Profit Margin value of 12.97%, SNY belongs to the best of the industry, outperforming 88.11% of the companies in the same industry.
SNY's Profit Margin has improved in the last couple of years.
The Operating Margin of SNY (22.04%) is better than 87.57% of its industry peers.
SNY's Operating Margin has improved in the last couple of years.
The Gross Margin of SNY (70.04%) is better than 74.05% of its industry peers.
In the last couple of years the Gross Margin of SNY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 22.04% | ||
| PM (TTM) | 12.97% | ||
| GM | 70.04% |
OM growth 3Y0.02%
OM growth 5Y3.47%
PM growth 3Y-6.53%
PM growth 5Y12.13%
GM growth 3Y0.71%
GM growth 5Y0.58%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), SNY is creating value.
SNY has less shares outstanding than it did 1 year ago.
SNY has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, SNY has an improved debt to assets ratio.
2.2 Solvency
SNY has a Debt/Equity ratio of 0.17. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.17, SNY perfoms like the industry average, outperforming 43.78% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.17 | ||
| Debt/FCF | N/A | ||
| Altman-Z | N/A |
ROIC/WACC2.18
WACC7.16%
2.3 Liquidity
SNY has a Current Ratio of 1.46. This is a normal value and indicates that SNY is financially healthy and should not expect problems in meeting its short term obligations.
SNY's Current ratio of 1.46 is on the low side compared to the rest of the industry. SNY is outperformed by 75.14% of its industry peers.
SNY has a Quick Ratio of 1.46. This is a bad value and indicates that SNY is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.74, SNY is not doing good in the industry: 87.57% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.46 | ||
| Quick Ratio | 0.74 |
3. Growth
3.1 Past
SNY shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.30%.
The Earnings Per Share has been growing slightly by 5.10% on average over the past years.
The Revenue has grown by 31.50% in the past year. This is a very strong growth!
SNY shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.31% yearly.
EPS 1Y (TTM)-5.3%
EPS 3Y5.45%
EPS 5Y5.1%
EPS Q2Q%-21.08%
Revenue 1Y (TTM)31.5%
Revenue growth 3Y4.17%
Revenue growth 5Y3.31%
Sales Q2Q%-3.25%
3.2 Future
Based on estimates for the next years, SNY will show a small growth in Earnings Per Share. The EPS will grow by 7.71% on average per year.
Based on estimates for the next years, SNY will show a small growth in Revenue. The Revenue will grow by 4.90% on average per year.
EPS Next Y8.29%
EPS Next 2Y9.51%
EPS Next 3Y10.06%
EPS Next 5Y7.71%
Revenue Next Year6.46%
Revenue Next 2Y6.39%
Revenue Next 3Y6.87%
Revenue Next 5Y4.9%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 13.62, which indicates a correct valuation of SNY.
88.65% of the companies in the same industry are more expensive than SNY, based on the Price/Earnings ratio.
SNY is valuated cheaply when we compare the Price/Earnings ratio to 29.63, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 12.56, SNY is valued correctly.
Based on the Price/Forward Earnings ratio, SNY is valued cheaply inside the industry as 85.41% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 22.68. SNY is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.62 | ||
| Fwd PE | 12.56 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
SNY's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The excellent profitability rating of SNY may justify a higher PE ratio.
PEG (NY)1.64
PEG (5Y)2.67
EPS Next 2Y9.51%
EPS Next 3Y10.06%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 3.57%, SNY has a reasonable but not impressive dividend return.
Compared to an average industry Dividend Yield of 4.35, SNY pays a better dividend. On top of this SNY pays more dividend than 93.51% of the companies listed in the same industry.
SNY's Dividend Yield is rather good when compared to the S&P500 average which is at 2.29.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.57% |
5.2 History
The dividend of SNY has a limited annual growth rate of 3.34%.
SNY has paid a dividend for at least 10 years, which is a reliable track record.
The dividend of SNY decreased recently.
Dividend Growth(5Y)3.34%
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
SNY's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP0%
EPS Next 2Y9.51%
EPS Next 3Y10.06%
54.46
+0.33 (+0.61%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners45.52%
Inst Owner Change-7.79%
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap136.54B
Analysts80
Price Target60.52 (11.13%)
Short Float %0.22%
Short Ratio1.96
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.57% |
Yearly Dividend3.56
Dividend Growth(5Y)3.34%
DP0%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.16%
Min EPS beat(2)-2.18%
Max EPS beat(2)14.5%
EPS beat(4)3
Avg EPS beat(4)4.59%
Min EPS beat(4)-2.18%
Max EPS beat(4)14.5%
EPS beat(8)5
Avg EPS beat(8)2.9%
EPS beat(12)8
Avg EPS beat(12)3.44%
EPS beat(16)12
Avg EPS beat(16)4.38%
Revenue beat(2)1
Avg Revenue beat(2)-0.45%
Min Revenue beat(2)-4.57%
Max Revenue beat(2)3.66%
Revenue beat(4)2
Avg Revenue beat(4)0.11%
Min Revenue beat(4)-4.57%
Max Revenue beat(4)3.66%
Revenue beat(8)2
Avg Revenue beat(8)-1.5%
Revenue beat(12)6
Avg Revenue beat(12)19.16%
Revenue beat(16)10
Avg Revenue beat(16)28.08%
PT rev (1m)0.7%
PT rev (3m)-3.37%
EPS NQ rev (1m)-14.87%
EPS NQ rev (3m)-15.33%
EPS NY rev (1m)-4.66%
EPS NY rev (3m)-4.68%
Revenue NQ rev (1m)-8.9%
Revenue NQ rev (3m)-7.59%
Revenue NY rev (1m)-2.18%
Revenue NY rev (3m)-4.71%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.62 | ||
| Fwd PE | 12.56 | ||
| P/S | 1.42 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.68 | ||
| P/tB | 11.43 | ||
| EV/EBITDA | N/A |
EPS(TTM)4
EY7.34%
EPS(NY)4.34
Fwd EY7.96%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS38.34
BVpS32.36
TBVpS4.76
PEG (NY)1.64
PEG (5Y)2.67
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9% | ||
| ROE | 15.37% | ||
| ROCE | 19.55% | ||
| ROIC | 15.58% | ||
| ROICexc | 16.79% | ||
| ROICexgc | 53.71% | ||
| OM | 22.04% | ||
| PM (TTM) | 12.97% | ||
| GM | 70.04% | ||
| FCFM | N/A |
ROA(3y)5.07%
ROA(5y)6.23%
ROE(3y)8.63%
ROE(5y)10.88%
ROIC(3y)7.46%
ROIC(5y)7.05%
ROICexc(3y)8.27%
ROICexc(5y)7.94%
ROICexgc(3y)35.84%
ROICexgc(5y)35.27%
ROCE(3y)9.37%
ROCE(5y)8.86%
ROICexcg growth 3Y-11.4%
ROICexcg growth 5Y0.08%
ROICexc growth 3Y1.08%
ROICexc growth 5Y3.67%
OM growth 3Y0.02%
OM growth 5Y3.47%
PM growth 3Y-6.53%
PM growth 5Y12.13%
GM growth 3Y0.71%
GM growth 5Y0.58%
F-ScoreN/A
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.17 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.46 | ||
| Quick Ratio | 0.74 | ||
| Altman-Z | N/A |
F-ScoreN/A
WACC7.16%
ROIC/WACC2.18
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.3%
EPS 3Y5.45%
EPS 5Y5.1%
EPS Q2Q%-21.08%
EPS Next Y8.29%
EPS Next 2Y9.51%
EPS Next 3Y10.06%
EPS Next 5Y7.71%
Revenue 1Y (TTM)31.5%
Revenue growth 3Y4.17%
Revenue growth 5Y3.31%
Sales Q2Q%-3.25%
Revenue Next Year6.46%
Revenue Next 2Y6.39%
Revenue Next 3Y6.87%
Revenue Next 5Y4.9%
EBIT growth 1Y21.75%
EBIT growth 3Y4.19%
EBIT growth 5Y6.9%
EBIT Next Year46.35%
EBIT Next 3Y16.93%
EBIT Next 5Y9.92%
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A